Table of Content



1. Research Scope & Methodology
1.1. Study Objectives
1.2. Methodology
1.3. Assumptions & Limitations

2. Executive Summary
2.1. Market Size & Estimates
2.2. Market Overview
2.3. Scope Of Study
2.4. Crisis Scenario Analysis
2.4.1. Impact Of Covid-19 On The Global Alzheimer’S Disease Therapeutics & Diagnostics Market
2.5. Major Market Findings
2.5.1. Growing R&D Investment In The Biomarkers For Early Detection Of Dementia
2.5.2. Increasing Demand For The Personalized Medicines

3. Market Dynamics
3.1. Parent Market Analysis
3.2. Key Drivers
3.2.1. Increase In Alzheimer’S Disease Cases
3.2.2. Advancements In Diagnostic Technologies
3.2.3. Growth In The Number Of Drugs Under Development
3.2.4. Expansion Of The Elderly Population
3.3. Key Restraints
3.3.1. Limited Availability Of Surrogate Markers
3.3.2. Late-Stage Drug Failures
3.3.3. Strict Government Regulations

4. Key Analytics
4.1. Key Market Trends
4.1.1. Advancements In In-Vitro Diagnostic Techniques
4.1.2. Usage Of Computed Tomography In The Diagnostics Of Alzheimer’S Disease
4.2. Porter’S Five Forces Analysis
4.2.1. Buyers Power
4.2.2. Suppliers Power
4.2.3. Substitution
4.2.4. New Entrants
4.2.5. Industry Rivalry
4.3. Growth Prospect Mapping
4.3.1. Growth Prospect Mapping For North America
4.3.2. Growth Prospect Mapping For Europe
4.3.3. Growth Prospect Mapping For Asia-Pacific
4.3.4. Growth Prospect Mapping For Rest Of World
4.4. Market Maturity Analysis
4.5. Market Concentration Analysis
4.6. Value Chain Analysis
4.6.1. R&D
4.6.2. Raw Material
4.6.3. Manufacturing
4.6.4. Wholesalers/Distributors/Retailers
4.6.5. End-User
4.7. Key Buying Criteria
4.7.1. Price
4.7.2. Efficiency
4.7.3. Safety
4.8. Etymology Of The Global Alzheimer’S Disease Therapeutics & Diagnostics Market
4.9. Phases And Sternness Of Alzheimer’S Disease

5. Market By Product
5.1. Therapeutics
5.1.1. Cholinesterase Inhibitors
5.1.2. Nmda Receptor Antagonists
5.1.3. Other Therapeutics
5.2. Diagnostics
5.2.1. Brain Imaging
5.2.2. Csf Test For Alzheimer’S Disease
5.2.3. Other Diagnostics

6. Geographical Analysis
6.1. North America
6.1.1. Market Size & Estimates
6.1.2. North America Alzheimer’S Disease Therapeutics & Diagnostics Market Drivers
6.1.3. North America Alzheimer’S Disease Therapeutics & Diagnostics Market Challenges
6.1.4. North America Alzheimer’S Disease Therapeutics & Diagnostics Market Regulatory Framework
6.1.5. Key Players In North America Alzheimer’S Disease Therapeutics & Diagnostics Market
6.1.6. Country Analysis
6.1.6.1. United States
6.1.6.1.1. United States Alzheimer’S Disease Therapeutics & Diagnostics Market Size & Opportunities
6.1.6.2. Canada
6.1.6.2.1. Canada Alzheimer’S Disease Therapeutics & Diagnostics Market Size & Opportunities
6.2. Europe
6.2.1. Market Size & Estimates
6.2.2. Europe Alzheimer’S Disease Therapeutics & Diagnostics Market Drivers
6.2.3. Europe Alzheimer’S Disease Therapeutics & Diagnostics Market Challenges
6.2.4. Europe Alzheimer’S Disease Therapeutics & Diagnostics Market Regulatory Framework
6.2.5. Key Players In Europe Alzheimer’S Disease Therapeutics & Diagnostics Market
6.2.6. Country Analysis
6.2.6.1. United Kingdom
6.2.6.1.1. United Kingdom Alzheimer’S Disease Therapeutics & Diagnostics Market Size & Opportunities
6.2.6.2. Germany
6.2.6.2.1. Germany Alzheimer’S Disease Therapeutics & Diagnostics Market Size & Opportunities
6.2.6.3. France
6.2.6.3.1. France Alzheimer’S Disease Therapeutics & Diagnostics Market Size & Opportunities
6.2.6.4. Italy
6.2.6.4.1. Italy Alzheimer’S Disease Therapeutics & Diagnostics Market Size & Opportunities
6.2.6.5. Belgium
6.2.6.5.1. Belgium Alzheimer’S Disease Therapeutics & Diagnostics Market Size & Opportunities
6.2.6.6. Poland
6.2.6.6.1. Poland Alzheimer’S Disease Therapeutics & Diagnostics Market Size & Opportunities
6.2.6.7. Rest Of Europe
6.2.6.7.1. Rest Of Europe Alzheimer’S Disease Therapeutics & Diagnostics Market Size & Opportunities
6.3. Asia-Pacific
6.3.1. Market Size & Estimates
6.3.2. Asia-Pacific Alzheimer’S Disease Therapeutics & Diagnostics Market Drivers
6.3.3. Asia-Pacific Alzheimer’S Disease Therapeutics & Diagnostics Market Challenges
6.3.4. Asia-Pacific Alzheimer’S Disease Therapeutics & Diagnostics Market Regulatory Framework
6.3.5. Key Players In Asia-Pacific Alzheimer’S Disease Therapeutics & Diagnostics Market
6.3.6. Country Analysis
6.3.6.1. China
6.3.6.1.1. China Alzheimer’S Disease Therapeutics & Diagnostics Market Size & Opportunities
6.3.6.2. Japan
6.3.6.2.1. Japan Alzheimer’S Disease Therapeutics & Diagnostics Market Size & Opportunities
6.3.6.3. India
6.3.6.3.1. India Alzheimer’S Disease Therapeutics & Diagnostics Market Size & Opportunities
6.3.6.4. South Korea
6.3.6.4.1. South Korea Alzheimer’S Disease Therapeutics & Diagnostics Market Size & Opportunities
6.3.6.5. Thailand
6.3.6.5.1. Thailand Alzheimer’S Disease Therapeutics & Diagnostics Market Size & Opportunities
6.3.6.6. Vietnam
6.3.6.6.1. Vietnam Alzheimer’S Disease Therapeutics & Diagnostics Market Size & Opportunities
6.3.6.7. Indonesia
6.3.6.7.1. Indonesia Alzheimer’S Disease Therapeutics & Diagnostics Market Size & Opportunities
6.3.6.8. Australia & New Zealand
6.3.6.8.1. Australia & New Zealand Alzheimer’S Disease Therapeutics & Diagnostics Market Size & Opportunities
6.3.6.9. Rest Of Asia-Pacific
6.3.6.9.1. Rest Of Asia-Pacific Alzheimer’S Disease Therapeutics & Diagnostics Market Size & Opportunities
6.4. Rest Of World
6.4.1. Market Size & Estimates
6.4.2. Rest Of World Alzheimer’S Disease Therapeutics & Diagnostics Market Drivers
6.4.3. Rest Of World Alzheimer’S Disease Therapeutics & Diagnostics Market Challenges
6.4.4. Rest Of World Alzheimer’S Disease Therapeutics & Diagnostics Regulatory Framework
6.4.5. Key Players In Rest Of World Alzheimer’S Disease Therapeutics & Diagnostics Market
6.4.6. Regional Analysis
6.4.6.1. Latin America
6.4.6.1.1. Latin America Alzheimer’S Disease Therapeutics & Diagnostics Market Size & Opportunities
6.4.6.2. Middle East & Africa
6.4.6.2.1. Middle East & Africa Alzheimer’S Disease Therapeutics & Diagnostics Market Size & Opportunities

7. Competitive Landscape
7.1. Key Strategic Developments
7.1.1. Mergers & Acquisitions
7.1.2. Product Launches & Developments
7.1.3. Partnerships & Agreements
7.1.4. Business Expansions & Divestitures
7.2. Company Profiles
7.2.1. Baxter International Inc
7.2.1.1. Company Overview
7.2.1.2. Product List
7.2.1.3. Strengths & Challenges
7.2.2. Allergan Plc (Acquired By Abbvie)
7.2.2.1. Company Overview
7.2.2.2. Product List
7.2.2.3. Strengths & Challenges
7.2.3. Biogen Inc
7.2.3.1. Company Overview
7.2.3.2. Product List
7.2.3.3. Strengths & Challenges
7.2.4. Cognoptix Inc
7.2.4.1. Company Overview
7.2.4.2. Product List
7.2.4.3. Strengths & Challenges
7.2.5. Eli Lilly And Company
7.2.5.1. Company Overview
7.2.5.2. Product List
7.2.5.3. Strengths & Challenges
7.2.6. F Hoffmann-La Roche
7.2.6.1. Company Overview
7.2.6.2. Product List
7.2.6.3. Strengths & Challenges
7.2.7. Lupin Limited
7.2.7.1. Company Overview
7.2.7.2. Products List
7.2.7.3. Strengths & Challenges
7.2.8. Merck & Co Inc
7.2.8.1. Company Overview
7.2.8.2. Product List
7.2.8.3. Strengths & Challenges
7.2.9. Novartis Ag
7.2.9.1. Company Overview
7.2.9.2. Products List
7.2.9.3. Strengths & Challenges
7.2.10. Sun Pharmaceuticals Industries Ltd
7.2.10.1. Company Overview
7.2.10.2. Product List
7.2.10.3. Strengths & Challenges
7.2.11. Pfizer Inc
7.2.11.1. Company Overview
7.2.11.2. Products List
7.2.11.3. Strengths & Challenges
7.2.12. Eisai Co Ltd
7.2.12.1. Company Overview
7.2.12.2. Product List
7.2.12.3. Strengths & Challenges
7.2.13. Johnson & Johnson
7.2.13.1. Company Overview
7.2.13.2. Product List
7.2.13.3. Strengths & Challenges
7.2.14. Ge Healthcare
7.2.14.1. Company Overview
7.2.14.2. Product List
7.2.14.3. Strengths & Challenges



List of Figures

List Of Figures
Figure 1: Key Market Trends
Figure 2: Porter’S Five Forces Analysis
Figure 3: Growth Prospect Mapping For North America
Figure 4: Growth Prospect Mapping For Europe
Figure 5: Growth Prospect Mapping For Asia-Pacific
Figure 6: Growth Prospect Mapping For Rest Of World
Figure 7: Market Maturity Analysis
Figure 8: Market Concentration Analysis
Figure 9: Value Chain Analysis
Figure 10: Key Buying Criteria
Figure 11: Global Alzheimer’S Disease Therapeutics & Diagnostics Market, Growth Potential, By Product, In 2023
Figure 12: Global Alzheimer’S Disease Therapeutics & Diagnostics Market, By Therapeutics, 2024-2032 (In $ Million)
Figure 13: Global Alzheimer’S Disease Therapeutics & Diagnostics Market, Growth Potential, By Therapeutics, In 2023
Figure 14: Global Alzheimer’S Disease Therapeutics & Diagnostics Market, By Cholinesterase Inhibitors, 2024-2032 (In $ Million)
Figure 15: Global Alzheimer’S Disease Therapeutics & Diagnostics Market, By Nmda Receptor Antagonists, 2024-2032 (In $ Million)
Figure 16: Global Alzheimer’S Disease Therapeutics & Diagnostics Market, By Other Therapeutics, 2024-2032 (In $ Million)
Figure 17: Global Alzheimer’S Disease Therapeutics & Diagnostics Market, By Diagnostics, 2024-2032 (In $ Million)
Figure 18: Global Alzheimer’S Disease Therapeutics & Diagnostics Market, Growth Potential, By Diagnostics, In 2023
Figure 19: Global Alzheimer’S Disease Therapeutics & Diagnostics Market, By Brain Imaging, 2024-2032 (In $ Million)
Figure 20: Global Alzheimer’S Disease Therapeutics & Diagnostics Market, By Csf Test For Alzheimer’S Disease, 2024-2032 (In $ Million)
Figure 21: Global Alzheimer’S Disease Therapeutics & Diagnostics Market, By Other Diagnostics, 2024-2032 (In $ Million)
Figure 22: North America Alzheimer’S Disease Therapeutics & Diagnostics Market, Country Outlook, 2023 & 2032 (In %)
Figure 23: United States Alzheimer’S Disease Therapeutics & Diagnostics Market, 2024-2032 (In $ Million)
Figure 24: Canada Alzheimer’S Disease Therapeutics & Diagnostics Market, 2024-2032 (In $ Million)
Figure 25: Europe Alzheimer’S Disease Therapeutics & Diagnostics Market, Country Outlook, 2023 & 2032 (In %)
Figure 26: United Kingdom Alzheimer’S Disease Therapeutics & Diagnostics Market, 2024-2032 (In $ Million)
Figure 27: Germany Alzheimer’S Disease Therapeutics & Diagnostics Market, 2024-2032 (In $ Million)
Figure 28: France Alzheimer’S Disease Therapeutics & Diagnostics Market, 2024-2032 (In $ Million)
Figure 29: Italy Alzheimer’S Disease Therapeutics & Diagnostics Market, 2024-2032 (In $ Million)
Figure 30: Belgium Alzheimer’S Disease Therapeutics & Diagnostics Market, 2024-2032 (In $ Million)
Figure 31: Poland Alzheimer’S Disease Therapeutics & Diagnostics Market, 2024-2032 (In $ Million)
Figure 32: Rest Of Europe Alzheimer’S Disease Therapeutics & Diagnostics Market, 2024-2032 (In $ Million)
Figure 33: Asia-Pacific Alzheimer’S Disease Therapeutics & Diagnostics Market, Country Outlook, 2023 & 2032 (In %)
Figure 34: China Alzheimer’S Disease Therapeutics & Diagnostics Market, 2024-2032 (In $ Million)
Figure 35: Japan Alzheimer’S Disease Therapeutics & Diagnostics Market, 2024-2032 (In $ Million)
Figure 36: India Alzheimer’S Disease Therapeutics & Diagnostics Market, 2024-2032 (In $ Million)
Figure 37: South Korea Alzheimer’S Disease Therapeutics & Diagnostics Market, 2024-2032 (In $ Million)
Figure 38: Thailand Alzheimer’S Disease Therapeutics & Diagnostics Market, 2024-2032 (In $ Million)
Figure 39: Vietnam Alzheimer’S Disease Therapeutics & Diagnostics Market, 2024-2032 (In $ Million)
Figure 40: Indonesia Alzheimer’S Disease Therapeutics & Diagnostics Market, 2024-2032 (In $ Million)
Figure 41: Australia & New Zealand Alzheimer’S Disease Therapeutics & Diagnostics Market, 2024-2032 (In $ Million)
Figure 42: Rest Of Asia-Pacific Alzheimer’S Disease Therapeutics & Diagnostics Market, 2024-2032 (In $ Million)
Figure 43: Rest Of World Alzheimer’S Disease Therapeutics & Diagnostics Market, Regional Outlook, 2023 & 2032 (In %)
Figure 44: Latin America Alzheimer’S Disease Therapeutics & Diagnostics Market, 2024-2032 (In $ Million)
Figure 45: Middle East & Africa Alzheimer’S Disease Therapeutics & Diagnostics Market, 2024-2032 (In $ Million)

List of Tables

LIST OF TABLES
TABLE 1: MARKET SNAPSHOT – ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS
TABLE 2: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY PRODUCT, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 3: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY PRODUCT, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 4: GLOBAL THERAPEUTICS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 5: GLOBAL THERAPEUTICS MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 6: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY THERAPEUTICS, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 7: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY THERAPEUTICS, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 8: GLOBAL CHOLINESTERASE INHIBITORS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 9: GLOBAL CHOLINESTERASE INHIBITORS MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 10: GLOBAL NMDA RECEPTOR ANTAGONISTS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 11: GLOBAL NMDA RECEPTOR ANTAGONISTS MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 12: GLOBAL OTHER THERAPEUTICS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 13: GLOBAL OTHER THERAPEUTICS MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 14: GLOBAL DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 15: GLOBAL DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 16: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY DIAGNOSTICS, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 17: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY DIAGNOSTICS, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 18: GLOBAL BRAIN IMAGING MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 19: GLOBAL BRAIN IMAGING MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 20: GLOBAL CSF TEST FOR ALZHEIMER’S DISEASE MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 21: GLOBAL CSF TEST FOR ALZHEIMER’S DISEASE MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 22: GLOBAL OTHER DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 23: GLOBAL OTHER DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 24: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY GEOGRAPHY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 25: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY GEOGRAPHY, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 26: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 27: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 28: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET REGULATORY FRAMEWORK
TABLE 29: KEY PLAYERS OPERATING IN NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
TABLE 30: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 31: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 32: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET REGULATORY FRAMEWORK
TABLE 33: KEY PLAYERS OPERATING IN EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
TABLE 34: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 35: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 36: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET REGULATORY FRAMEWORK
TABLE 37: KEY PLAYERS OPERATING IN ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
TABLE 38: REST OF WORLD ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 39: REST OF WORLD ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 40: REST OF WORLD ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET REGULATORY FRAMEWORK
TABLE 41: KEY PLAYERS OPERATING IN REST OF WORLD ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
TABLE 42: LIST OF MERGERS & ACQUISITIONS
TABLE 43: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 44: LIST OF PARTNERSHIPS & AGREEMENTS
TABLE 45: LIST OF BUSINESS EXPANSIONS & DIVESTITURES